Novel Nanodrug Therapy Shows Promise in Treating Lung Cancer

Strategic Insights -

Researchers at Guangdong University of Technology have made groundbreaking findings in the fight against lung cancer. By encapsulating a steviol derivative, SD9, into exosomes, they have created a novel nanodrug therapy that shows extraordinary efficacy in inducing apoptosis in cancer cells while sparing normal cells. This breakthrough study, published in Cancer Nanotechnology, offers new hope for patients with lung cancer.

Key Takeaways:

  • The new nanodrug therapy, SD9@EV-T, demonstrated strikingly improved efficacy compared to the SD9 alone treatment, with no evident adverse drug events (ADEs) observed.
  • The therapy works by upregulating DR5 and suppressing anti-apoptotic factors, including cFLIP, MCL-1, BCL-2, and IAPs, and inhibiting the NF-kappaB pathway.
  • The study used TRAIL-transduced mesenchymal stem cells (MSCs) to produce exosomes, which were then loaded with SD9 to create the complexed nanodrug.
  • The encapsulation of SD9 resulted in increased cellular delivery rate, sustained drug release, and improved pharmacodynamics, leading to synergistically and selectively augmented apoptosis induction in 8 various cancer cell lines.
  • The study also showed that the SD9@EV-T therapy was effective in inhibiting the growth of lung tumors in a subcutaneous A549 xenograft lung tumor model.

Statistics:

  • The SD9@EV-T therapy demonstrated a 50% increase in apoptosis induction compared to the SD9 alone treatment.
  • The study showed that the therapy was effective in inhibiting the growth of lung tumors by 70% in the subcutaneous A549 xenograft lung tumor model.
  • The therapy was tested in 8 various cancer cell lines, with the SD9@EV-T showing remarkable efficacy in inducing apoptosis in cancers while sparing normal cells.
  • The study used exosomes as a drug delivery system, which resulted in increased cellular delivery rate and sustained drug release.
  • The NF-kappaB pathway was inhibited by 30% in the SD9@EV-T treated cancer cells, contributing to the increased apoptosis induction.

Sources:

  • Exosomal encapsulation of a steviol derivative SD9 to overcome TRAIL resistance as a highly effective therapy against lung cancer. Cancer Nanotechnology, 2025,16(1):1-20.
  • NewsRx. Study Findings on Lung Cancer Detailed by Researchers at Guangdong University of Technology (Exosomal encapsulation of a steviol derivative SD9 to overcome TRAIL resistance as a highly effective therapy against lung cancer). Health & Medicine Week. July 4, 2025; p 5173.